KR100599460B1 - Food composition comprising of extracts of cricket having protective effects against hepatotoxicity - Google Patents
Food composition comprising of extracts of cricket having protective effects against hepatotoxicity Download PDFInfo
- Publication number
- KR100599460B1 KR100599460B1 KR1020040050837A KR20040050837A KR100599460B1 KR 100599460 B1 KR100599460 B1 KR 100599460B1 KR 1020040050837 A KR1020040050837 A KR 1020040050837A KR 20040050837 A KR20040050837 A KR 20040050837A KR 100599460 B1 KR100599460 B1 KR 100599460B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- group
- cricket
- tcdd
- hepatotoxicity
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 67
- 231100000304 hepatotoxicity Toxicity 0.000 title claims abstract description 20
- 206010019851 Hepatotoxicity Diseases 0.000 title claims abstract description 19
- 230000007686 hepatotoxicity Effects 0.000 title claims abstract description 19
- 235000013305 food Nutrition 0.000 title claims abstract description 12
- 230000001681 protective effect Effects 0.000 title description 3
- 239000000203 mixture Substances 0.000 title description 2
- 241000238814 Orthoptera Species 0.000 claims abstract description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000003449 preventive effect Effects 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- 241000238820 Gryllus bimaculatus Species 0.000 claims abstract description 5
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 abstract description 51
- 231100000167 toxic agent Toxicity 0.000 abstract description 6
- 239000003440 toxic substance Substances 0.000 abstract description 4
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 230000007056 liver toxicity Effects 0.000 abstract 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 9
- 239000012128 staining reagent Substances 0.000 description 8
- 241000238631 Hexapoda Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 150000002013 dioxins Chemical class 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 210000001367 artery Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 208000019899 phobic disease Diseases 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 206010034912 Phobia Diseases 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 210000000918 epididymis Anatomy 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100000334 hepatotoxic Toxicity 0.000 description 3
- 230000003082 hepatotoxic effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000004009 herbicide Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238816 Gryllidae Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000735242 Libanasidus vittatus Species 0.000 description 1
- WBNQDOYYEUMPFS-UHFFFAOYSA-N N-nitrosodiethylamine Chemical compound CCN(CC)N=O WBNQDOYYEUMPFS-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001804 chlorine Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002837 defoliant Substances 0.000 description 1
- 150000004827 dibenzo-1,4-dioxins Chemical class 0.000 description 1
- 150000004826 dibenzofurans Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000004730 hepatocarcinogenesis Effects 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/14—Yeasts or derivatives thereof
- A23L33/145—Extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Abstract
본 발명은 다이옥신 등과 같은 독성화합물에 의해 유발되는 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품에 관한 것으로서, 상기 추출물은 그릴러스 비마큘라투스(Gryllus bimaculatus) 속 아열대산 귀뚜라미의 건조된 성체 500g을 증류수 4,000 내지 6,000㎖ 중에서 열수추출하고, 수득된 열수추출액을 1/50 내지 1/55의 비율로 농축한 후, 동결건조시켜서 얻어지는 추출물을 유효농도로 적어도 200㎎/㎏을 포함하여 이루어짐을 특징으로 하는 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품을 제공한다.The present invention relates to a food comprising a cricket extract having a preventive effect on hepatotoxicity caused by a toxic compound such as dioxin, the extract is dried adult 500g of subtropical crickets of the genus Gryllus bimaculatus The hot water extract in 4,000 to 6,000 mL of distilled water, and the obtained hot water extract is concentrated at a ratio of 1/50 to 1/55, and then the extract obtained by lyophilization comprises at least 200 mg / kg to an effective concentration It provides a food comprising a cricket extract having a preventive effect on liver toxicity.
귀뚜라미, 추출물, 간독성, 다이옥신, TCDD Cricket, extract, hepatotoxicity, dioxin, TCDD
Description
도 1은 본 발명에 따라 다이옥신으로 유발되는 간독성에 기인하는 체중감소에 있어서 귀뚜라미 추출물의 투여 효과를 실험한 결과를 나타내는 그래프이다.1 is a graph showing the results of experiments in the administration of the cricket extract in weight loss due to hepatotoxicity induced by dioxin according to the present invention.
도 2는 본 발명에 따라 다이옥신으로 유발되는 간독성에 기인하는 혈액생화학적 변화에 있어서 귀뚜라미 추출물의 투여 효과를 실험한 결과를 나타내는 그래프이다.Figure 2 is a graph showing the results of experiments in the administration of the cricket extract in blood biochemical changes due to hepatotoxicity induced by dioxin according to the present invention.
도 3은 본 발명에 따라 다이옥신으로 유발되는 간독성에 기인하는 상대 장기중량의 변화에 있어서 귀뚜라미 추출물의 투여 효과를 실험한 결과를 나타내는 그래프이다.Figure 3 is a graph showing the results of experiments in the administration of the cricket extract in the change in relative organ weight due to hepatotoxicity induced by dioxin according to the present invention.
도 4는 본 발명의 실시예들에서 G1군(TCDD 처리없이 귀뚜라미 추출액이 포함되지 않은 생리식염수만을 쥐에게 경구투여한 군)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 100배율로 확대하여 촬영한 사진으로, 도 4(A)는 간세동이를 도 4(B)는 중심동맥 부분을 보여주고 있다.Figure 4 in the embodiments of the present invention stained liver tissue of rats of the G1 group (group orally administered to rats only saline containing no cricket extract without TCDD treatment) with hematoxylin / eosin staining reagent and 100 times 4 (A) shows the liver defibrillation and FIG. 4 (B) shows the central artery part.
도 5는 본 발명의 실시예들에서 G2군(귀뚜라미 추출액이 포함되지 않은 생리식염수만을 쥐에게 경구투여하였으며, 그후에 TCDD를 주사한 그룹)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 확대하여 촬영한 사진으로, 도 5(A)는 100배율의 확대사진이고, 도 5(B)는 200배율의 확대사진이다.Figure 5 in the embodiments of the present invention the liver tissue of the G2 group (oral administration of physiological saline not containing the cricket extract, and then injected with TCDD) stained with hematoxylin / eosin staining reagent 5 (A) is an enlarged photograph at 100 times magnification, and FIG. 5 (B) is an enlarged photograph at 200 magnifications.
도 6은 본 발명의 실시예들에서 G4군(귀뚜라미 추출액 100㎎/㎏을 쥐에게 경구투여하였으며, 그후에 TCDD를 주사한 그룹)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 100배율로 확대하여 촬영한 사진으로, 도 6(A)는 간세동이를 도 6(B)는 중심동맥 부분을 보여주고 있다.Figure 6 in the embodiments of the present invention the liver tissue of the G4 group (Cricket extract 100mg / kg orally administered to the rat, then injected with TCDD) mice stained with hematoxylin / eosin staining reagent and 100 6 (A) shows the liver defibrillation and FIG. 6 (B) shows the central artery part.
도 7은 본 발명의 실시예들에서 G5군(귀뚜라미 추출액 200㎎/㎏을 쥐에게 경구투여하였으며, 그후에 TCDD를 주사한 그룹)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 100배율로 확대하여 촬영한 사진으로, 도 6(A)는 간세동이를 도 6(B)는 중심동맥 부분을 보여주고 있다.Figure 7 in the embodiments of the present invention the liver tissue of rats of the G5 group (Cricket extract 200mg / kg orally administered to the rat, then injected with TCDD) mice stained with hematoxylin /
본 발명은 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품에 관한 것이다. 보다 상세하게는 본 발명은 다이옥신 등과 같은 독성화합물에 의해 유발되는 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품에 관한 것이다.The present invention relates to a food comprising a cricket extract having a preventive effect on hepatotoxicity. More specifically, the present invention relates to a food comprising a cricket extract having a protective effect against hepatotoxicity caused by toxic compounds such as dioxins.
우리나라에서 다이옥신이 문제가 되기 시작한 것은 베트남 전쟁에서 고엽제로 알려진 제초제에 다이옥신이 불순물로 함유되어 있었고, 이에 폭로된 참전군인과 그 후세들에게 여러 가지 건강장애가 나타난 것은 1990년대 초반의 일이다. 최근에는 쓰레기 소각장에서 다이옥신의 과다한 유출로 시민들의 관심을 받기에 이르렀으며, 또한 1997년 4월에는 마산만의 어패류에서 규정치 보다 310배나 높은 다이옥신이 검출되어 문제시 된 독성화합물이다.Dioxins began to be a problem in Korea in the early 1990s when dioxin was contained as an impurity in the herbicide known as the defoliant in the Vietnam War, and various health disorders appeared to veterans and their descendants. In recent years, the waste incinerator has attracted the attention of citizens due to the excessive leakage of dioxins, and in April 1997, fish and shellfish in Masan Bay were detected with dioxin, 310 times higher than the specified value.
다이옥신(dioxin)은 고리가 3개인 방향족 화하물에 여러 개의 염소가 붙어있는 화합물을 말하는 것으로서, 가운데 고리에 산소원자가 2개인 다이옥신계 화합물(polychlorinated dibenzo-p-dioxin ; PCDD)과 산소원자가 하나인 퓨란계 화합물(polychlorinated dibenzo furan ; PCDF)을 모두 통칭한다. 치환된 염소의 수 및 위치에 따라 PCDDs는 75개의 동종체, PCDFs는 135개의 동종체가 각각 존재하며 따라서 총 다이옥신류는 210개의 이성체가 있다. PCDDs는 제초제, 살충제 등의 화학제품, 쓰레기 소각장에서 나오는 유독성 매연, 제지공장으로부터 배출되는 오염된 물 등에 포함되어 우리의 주변 환경에 거의 반영구적으로 존재하며 인간과 동물의 체내에 농축되어 다양한 장애를 유발함으로써 인류의 미래를 위협하고 있다.Dioxin (dioxin) refers to a compound having several chlorine attached to an aromatic compound having three rings, a polychlorinated dibenzo-p-dioxin (PCDD) having two oxygen atoms in the middle ring and a furan having one oxygen atom. All compounds are called polychlorinated dibenzo furan (PCDF). Depending on the number and position of the substituted chlorine, there are 75 isoforms in PCDDs and 135 isoforms in PCDFs, so there are 210 isomers in total dioxins. PCDDs are almost semi-permanent in our environment and contain various chemicals such as herbicides, pesticides, toxic fumes from waste incinerators, and polluted water from paper mills. By threatening the future of humanity.
2,3,7,8-tetrachlorodibenzo-p-dioxin(TCDD)은 PCDDs의 동종체 중의 하나로 현재까지 알려진 다이옥신 중에서는 체내에서 가장 강한 독성을 유발하는 것으로 알려져 있다(Pohjanvirta R & Tuomisto J(1994) ; Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals; effects, mechanism, and animal models. Pharmacol. Rev. 46; 483-549). TCDD는 일부는 소변 및 담즙으로 배설되기는 하나, 지용성이 강해 체내 지방조직에 주로 축적되며, 화학적으로 안정된 특성을 가지고 있어 자연계에서 거의 분해되지 않아(체내 반감기 약 11년), 먹이사슬에 의해 농축된 것을 인간이 섭취하기 때문에 더욱 위험하다. TCDD에 의한 독성은 설치류에서 피부, 폐 등을 포함한 다양한 장기에 암을 유발하는 것으로 알려져 있으며, 고농도(30㎍/㎏ 이상)에서 지방조직 보다 간에 더 많이 축적된다. 특히 설치류의 간에서 강력한 발암물질로서 문제를 일으키는 것으로 보고되고 있다(Pitot HC, Goldsworthy T, Campbell HA & Poland A(1980) ; Quantitative evaluation of the promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin of hepatocarcinogenesis from diethylnitrosamine. Cancer Res. 40; 3616-3620).2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is one of the homologs of PCDDs and is known to cause the strongest toxicity in the body among the dioxins known to date (Pohjanvirta R & Tuomisto J (1994); Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in laboratory animals; effects, mechanism, and animal models.Pharmacol. Rev. 46; 483-549). TCDD is partly excreted in urine and bile, but it is fat-soluble and accumulates mainly in adipose tissue in the body, and has a chemically stable property, so it is hardly decomposed in nature (about 11 years of half-life in the body). It is even more dangerous because humans ingest things. Toxicity by TCDD is known to cause cancer in various organs, including skin, lungs, etc. in rodents, and accumulates more in the liver than fatty tissue at high concentrations (30 μg / kg or more). In particular, it has been reported to cause problems as a potent carcinogen in the rodent liver (Pitot HC, Goldsworthy T, Campbell HA & Poland A (1980); Quantitative evaluation of the promotion by 2,3,7,8-tetrachlorodibenzo-p-). dioxin of hepatocarcinogenesis from diethylnitrosamine.Cancer Res. 40; 3616-3620).
이것은 TCDD가 간의 대사과정에 중요한 씨토크롬 피-450(cytochrome P-450) 효소계 및 간세포의 증식과 산화적인 DNA의 손상 등에 영향을 줌으로써 간독성을 유발하는 것으로 추정되고 있다.This suggests that TCDD induces hepatotoxicity by affecting cytochrome P-450 enzyme system, which is important for liver metabolism, and proliferation of liver cells and damage of oxidative DNA.
한편 곤충은 주로 해충으로 인식되어 이들을 방제하는데 주력하였을 뿐, 유용성 곤충에 관한 연구는 아직 미진한 실정이다. 최근에 들어 곤충의 다양성과 특성을 새롭게 인식하면서 곤충의 생리활성물질을 산업적으로 이용하거나 의약품을 개발하는데 일부 곤충이 이용되고 있다.On the other hand, insects were mainly recognized as pests and focused on controlling them, but studies on useful insects are still insufficient. Recently, some insects have been used to industrially use the bioactive substances of insects or to develop medicines while newly recognizing the diversity and characteristics of insects.
안 등은 귀뚜라미 추출물이 오메가-3 계열 지방산을 포함한 불포화지방산이 풍부하며 단백질과 키틴/키토산을 높은 농도로 함유하고 있어 귀뚜라미 추출물을 축산물 사료에 첨가 시 계육에서 다가불포화 지방산 증가, 소량의 EPA 증가 및 육질이 향상되었다고 보고하였으며(Ahn MY, Ryu KS, Park BY, Kim DW, Kim I & Kim SH(2000) ; Effect of cricket on the chicken and its egg. Korean J. Poult. Sci. 27; 197-202), 또한 사염화탄소로 급성 간장해를 유발한 마우스에서 귀뚜라미 추출물의 간 보호 효과 및 수영능 증강 등의 효과를 보고하였다(Ahn MY, Lee YW, Ryu KS, Lee HS, Kim I, Kim JW, Lee YK, Kim ES & Kim YS(2002) ; Protective effects of water/methanol extracts of cricket on the acute hepatic damages in the ICR-mice induced by administration of CCl4. Korean J. Food Sci. Technol. 34(4);684-687).Cricket extract is rich in unsaturated fatty acids including omega-3 fatty acids and contains high concentrations of protein and chitin / chitosan. Therefore, when the cricket extract is added to animal feed, the polyunsaturated fatty acid is increased in poultry, a small increase in EPA and Ahn MY, Ryu KS, Park BY, Kim DW, Kim I & Kim SH (2000); Effect of cricket on the chicken and its egg.Korean J. Poult.Sci. 27; 197-202 In addition, we reported the effects of cricket extract on the liver protection and swimming ability in acute liver injury induced by carbon tetrachloride (Ahn MY, Lee YW, Ryu KS, Lee HS, Kim I, Kim JW, Lee YK). , Kim ES & Kim YS (2002); Protective effects of water / methanol extracts of cricket on the acute hepatic damages in the ICR-mice induced by administration of CCl 4.Korean J. Food Sci.Technol. 34 (4); 684-; 687).
본 발명의 목적은 다이옥신 등과 같은 독성화합물에 의해 유발되는 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품을 제공하는 데 있다.An object of the present invention is to provide a food comprising a cricket extract having a preventive effect on hepatotoxicity caused by toxic compounds such as dioxins.
본 발명에 따른 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품은, 그릴러스 비마큘라투스(Gryllus bimaculatus) 속 아열대산 귀뚜라미의 건조된 성체 500g을 증류수 4,000 내지 6,000㎖ 중에서 열수추출하고, 수득된 열수추출액을 1/50 내지 1/55의 비율로 농축한 후, 동결건조시켜서 얻어지는 추출물을 유효농도로 적어도 200㎎/㎏을 포함하여 이루어진다.Food containing a cricket extract having a preventive effect on hepatotoxicity according to the present invention, the dried adult 500g of subtropical crickets of the genus Gryllus bimaculatus hot water extracted in distilled water 4,000 to 6,000ml, The hot water extract is concentrated at a ratio of 1/50 to 1/55, and the extract obtained by lyophilization comprises at least 200 mg / kg as an effective concentration.
삭제delete
삭제delete
이하, 본 발명의 구체적인 실시예를 첨부한 도면을 참조하여 상세히 설명한다.Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명에 따른 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품은, 그릴러스 비마큘라투스(Gryllus bimaculatus) 속 아열대산 귀뚜라미의 건조된 성체 500g을 증류수 4,000 내지 6,000㎖ 중에서 열수추출하고, 수득된 열수추출액을 1/50 내지 1/55의 비율로 농축한 후, 동결건조시켜서 얻어지는 추출물을 유효농도로 적어도 200㎎/㎏을 포함하여 이루어짐을 특징으로 한다. 귀뚜라미는 우리의 생활환경 주변에서 흔히 볼 수 있는 귀뚜라미과(Gryllidae)에 속하는 곤충으로서, 본 발명에서는 특히 학명이 그릴러스 비마큘라투스(Gryllus bimaculatus)인 아열대산 귀뚜라미를 사용한다.Food comprising a cricket extract having a preventive effect on hepatotoxicity according to the present invention, the dried adult 500g of subtropical crickets of the genus Gryllus bimaculatus hot water extracted in distilled water 4,000 to 6,000ml, The hot water extract is concentrated at a ratio of 1/50 to 1/55, and the extract obtained by lyophilization is characterized in that it comprises at least 200 mg / kg to an effective concentration. Crickets are insects belonging to Gryllidae, which are commonly found around our living environment, and in the present invention, the subtropical crickets, especially the scientific name Gryllus bimaculatus, are used.
여름철 밤에 날개를 마찰하여 내는 울음소리로 정서곤충으로 알려져 있으나, 왕귀뚜라미는 과수나 각종 묘목을 갉아먹는 해충이지만 구워서 어린아이의 경기에 사용하면 효과가 있고, 해열제로도 사용한다고 한다. 일본 애히매겐과 오이따 등지에서는 성충을 설사와 이질병에 사용하였고, 또 장티프스에는 성충을 눌러서 짠 즙액을 술에 타 마셨으며, 또 꾸지마에서는 엑기스를 해열제로 사용하는 습속이 있는 것으로 알려져 있다. 그러나 일반적으로 상용화되지는 못하고 있으며, 현재 미국에서 주메드사(Zoomed)에서 파충류, 물고기 사료로 귀뚜라미가 판매되고 있을 뿐이다. 본 발명에서는 이러한 귀뚜라미의 열수추출물이 독성물질에 의한 간독성을 예방할 수 있음을 발견하고, 생화학적 실험을 통해 특히 간독성에 유효한 유효농도를 결정하여 완성된 용도발명으로서의 특징이 있는 것이다. 상기 귀뚜라미 추출물의 제조에 있어서, 건조된 성체 귀뚜라미 500g에 대해 열수추출을 위한 증류수가 4,000㎖ 미만인 경우, 유효물질의 추출이 충분히 일어나지 않게 되는 문제점이 있을 수 있으며, 6,000㎖을 초과하는 경우, 가열 등을 위한 열수추출에 시간과 노력 및 에너지가 많이 소요되어 경제적이지 못하고, 생산성이 저하되는 문제점이 있을 수 있다. 또한, 보관, 취급 등을 간편하게 하기 위하여 수득된 열수추출액을 1/50 내지 1/55의 비율로 농축한 후, 동결건조시키는 것으로 이루어진다. Although it is known as an emotional insect because of the sound of rubbing wings at summer night, the king cricket is a pest that eats fruit trees and various seedlings, but it is effective when baked and used in children's games. In Ahimagen and Oita, Japan, adults were used for diarrhea and dysentery. In typhoids, the adult juices were pressed by drinking them, and it was known that there was a custom to use extract as an antipyretic. However, in general, it is not commercially available, and crickets are currently sold in the United States at Zoomed as feed for reptiles and fish. In the present invention, it was found that the hot water extract of cricket can prevent hepatotoxicity caused by toxic substances, and it is characterized as a complete use invention by determining the effective concentration effective for hepatotoxicity through biochemical experiments. In the production of the cricket extract, if the distilled water for hot water extraction for less than 500g of the dried adult crickets, there may be a problem that the extraction of the active substance does not occur sufficiently, in the case of exceeding 6,000ml, heating, etc. It takes a lot of time, effort and energy to extract the hot water for economical, there may be a problem that productivity is lowered. Further, in order to simplify storage, handling, etc., the obtained hot water extract is concentrated at a ratio of 1/50 to 1/55, and then lyophilized.
삭제delete
삭제delete
상기 식품에서 귀뚜라미 추출물의 유효농도는 이하의 실시예 및 실험예에서 실험적으로 확정된 것으로서, 특히 복용대상체의 체중 당 독성화합물에 의해 유발되는 간독성을 예방하기에 적절하고 효과가 있는 농도로서, 이 농도 미만인 경우, 목적하는 바의 간독성의 예방효과가 충분치 못하게 되는 문제점이 있을 수 있다.The effective concentration of cricket extract in the food is experimentally confirmed in the following Examples and Experimental Examples, and is a concentration suitable and effective to prevent hepatotoxicity caused by toxic compounds per body weight of the subject. If less, there may be a problem that the desired effect of preventing hepatotoxicity is not sufficient.
이하에서 본 발명의 바람직한 실시예 및 비교예들이 기술되어질 것이다.Hereinafter, preferred embodiments and comparative examples of the present invention will be described.
이하의 실시예들은 본 발명을 예증하기 위한 것으로서 본 발명의 범위를 국한시키는 것으로 이해되어져서는 안될 것이다.The following examples are intended to illustrate the invention and should not be understood as limiting the scope of the invention.
실시예Example
건조된 성체 귀뚜라미 500g을 증류수 5,000㎖ 중에서 열수추출하고, 수득된 열수추출액을 1/50의 비율로 농축한 후, 동결건조시켜서 귀뚜라미 추출물을 수득하였다.500 g of dried adult crickets were extracted with hot water in 5,000 ml of distilled water, and the obtained hot water extract was concentrated at a ratio of 1/50, and then lyophilized to obtain a cricket extract.
실험예Experimental Example
시험물질의 보관 및 취급Storage and Handling of Test Substances
시험물질(상기 실시예의 귀뚜라미 추출물)은 기밀용기에 담아 보관하였다.Test substance (cricket extract of the above example) was stored in an airtight container.
간독성 유발물질Hepatotoxic substances
간독성 유발물질로는 2,3,7,8-tetrachlorodibenzo-p-dioxin(TCDD)을 사용하였다. 이 간독성 유발물질은 갈색시약병에 담아 냉장보관하였다.2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was used as a hepatotoxic agent. The hepatotoxic agents were stored in brown reagent bottles and refrigerated.
시험계는 스프라그-돌리(Sprague-Dawley ; SD) 랫드(대한민국 소재 (주)샘타코바이오코리아 공급) 6주령(190 내지 200g) 40마리를 구입하여 7일간의 순화기간을 두어 사육한 후, 7주령(209 내지 223g) 35마리를 선별하여 사용하였다. SD 랫드는 일반독성 및 약효약리 시험에 널리 사용되고 있으며, 참고할 많은 기초자료가 축적되어 있어 시험계로 선택하였다.The test system purchased 40 Sprague-Dawley (SD) rats (Sampacobio Korea, South Korea) 6 weeks of age (190 to 200g) and raised for 7 days, and then raised them. 35 rats of age (209-223 g) were selected and used. SD rats are widely used in general toxicity and pharmacological tests, and a lot of basic data are available for reference.
시험군 구성Test group composition
시험군은 하기 표 1과 같이 구성하였다.The test group was configured as shown in Table 1 below.
투여경로Route of administration
귀뚜라미 추출물(실시예)의 임상예상적용경로가 경구이므로 투여경로를 경구로 하였으며, TCDD는 복강으로 투여하였다.The clinical route of application of cricket extract (Example) was oral, so the route of administration was oral, and TCDD was administered intraperitoneally.
투여방법Dosing method
귀뚜라미 추출물(실시예)은 군분리 다음날부터 1회/1일 경구로 존데(sonde)를 이용해서 위내로 14일간 투여하였으며, TCDD는 귀뚜라미 추출물의 투여가 끝난 다음날에 23게이지의 주사기를 이용하여 복강 내로 투여하였다.Cricket extract (Example) was administered orally once daily for 1 day from the day after group separation using sonde, and TCDD was intraperitoneally using a 23-gauge syringe the day after the cricket extract was finished. Administered into.
시험방법Test Methods
시험기간 : 28일(귀뚜라미 추출물 투여기간 14일 + TCDD 투여 후 관찰기간 14일)Trial period: 28 days (14 days for cricket extract administration + 14 days for observation after TCDD administration)
투여는 군분리 다음날부터 14일간 음성대조군(G1) 및 양성대조군(G2)에는 생리식염수를, 투여군(G3 내지 G5)에는 귀뚜라미 추출물을 각 용량별로 경구투여 하였다.The administration was orally administered to each dose for 14 days from the day after the group separation, saline in the negative control group (G1) and positive control group (G2), and cricket extract in the administration group (G3 to G5).
TCDD는 14일간 생리식염수 및 귀뚜라미 추출물을 투여한 후, TCDD(2㎎)를 미량의 디메틸설폭사이드(DMSO)(50㎕)와 소량의 아세톤(450㎕)에 녹인 다음 옥수수유(corn oil)(4.5㎖)에 희석한 것을 스톡솔루션(stock solution ; 400㎍/㎖)으로 하였으며, 워킹솔루션(working solution)은 TCDD의 최종농도가 60㎍/㎖가 되도록 옥수수유로 희석한 다음 복강투여하였다. TCDD를 투여한 후, 14일간은 귀뚜라미 추출물을 투여하지 않았으며 관찰만을 하였다.TCDD was administered with saline and cricket extracts for 14 days, followed by dissolving TCDD (2 mg) in a trace amount of dimethyl sulfoxide (DMSO) (50 μl) and a small amount of acetone (450 μl), followed by corn oil ( 4.5 ml) was used as a stock solution (400 µg / ml), and the working solution was diluted with corn oil so that the final concentration of TCDD was 60 µg / ml and then intraperitoneally administered. After the administration of TCDD, no cricket extract was administered for 14 days, only observations were made.
일반증상 관찰General symptoms observation
일반증상은 귀뚜라미 추출물 투여기간 중 1일 1회 매일 관찰하고, 관찰기간 중 1일 2회 사망개체 발생여부를 확인하였다.General symptoms were observed once a day during the cricket extract administration period, and confirmed whether death occurred twice a day during the observation period.
체중측정Weight measurement
시험에 사용된 시험동물의 체중은 예비 군분리시, 귀뚜라미 추출물 투여 개시 후, 주 2회 및 부검직전에 측정하였다. 부검직전에 약 18시간 동안 절식을 시켰다.Body weights of the test animals used for the test were measured twice a week after the start of cricket extract administration and immediately before necropsy during the preliminary group separation. Fasting was performed for about 18 hours immediately before autopsy.
혈액생화학적 검사Blood biochemical test
혈액생화학적 검사는 부검시에 18시간 절식시킨 동물을 에테르 마취하에 복대동맥에서 전채혈해서 얻은 혈액을 실온에 30분간 방치하여 응고시킨 다음 원심분리(3,000rpm, 15분)해서 얻은 혈청에 대하여 alanine transaminase(ALT), aspartate transaminase(AST), alkaline phosphatase(ALP), triglyceride, cholesterol, high-density lipoprotein(HDL), low-density lipoprotein(LDL), glucose, creatinine, total protein, albumin, uric acid, blood urea nitrogen(BUN), calcium, inorganic phosphate치를 자동분석기(히다치-747(Hitachi-747), 일본국 소재 히다치 메디칼 사(Hitachi Medical Co., LTD,)를 이용하여 측정하였다.Blood biochemical tests showed that the animals obtained by fasting for 18 hours at necropsy were pre-bleeded from the abdominal aorta under ether anesthesia for 30 minutes at room temperature to coagulate, and then alanine the serum obtained by centrifugation (3,000 rpm, 15 minutes). transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), triglyceride, cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), glucose, creatinine, total protein, albumin, uric acid, blood The urea nitrogen (BUN), calcium, and inorganic phosphate values were measured using an automatic analyzer (Hitachi-747, Hitachi Medical Co., Ltd., Japan).
장기중량 측정Long-term weight measurement
시험종료 후 모든 시험동물에 대하여 간장, 심장, 비장, 신장(좌, 우), 고환(좌, 우), 부고환(좌, 우), 전립샘, 폐, 흉선, 부신(좌, 우), 갑상샘(좌, 우), 악하샘(좌, 우), 뇌의 장기중량을 측정하였다.After completion of the test, all test animals were treated with liver, heart, spleen, kidney (left and right), testicles (left and right), epididymis (left and right), prostate, lung, thymus, adrenal gland (left and right) and thyroid gland ( Left, right), submandibular glands (left, right) and brain organ weights were measured.
병리조직 검사Histopathology
간을 채취하여 10% 중성 포르말린에 고정시켰다. 충분한 고정을 거친 간 조직은 파라핀 포매기(Leica EG 116, 독일)에 포매하여 로타리 마이크로톰(Leica 820, 스웨덴)으로 4㎕ 절편을 만들어 헤마톡실린 및 에오신(Hematoxylin & Eosin) 염색을 하여 광학현미경으로 검사하였다.Livers were harvested and fixed in 10% neutral formalin. After sufficient fixation, the liver tissue was embedded in a paraffin embeder (Leica EG 116, Germany) and made into 4 µl sections using a rotary microtome (Leica 820, Sweden) and stained with hematoxylin and Eosin under an optical microscope. Inspected.
자료의 통계처리Statistical processing of data
대조군과 실험군의 체중변화, 장기중량 및 혈청생화학적 검사에 대한 실험결과는 평균치± 표준편차로 표시하였고, 스튜던츠 티-테스트(Student's t-test)법을 이용하여 통계학적 유의성을 결정하였다.The experimental results for weight change, organ weight, and serum biochemical test of the control group and the experimental group were expressed as mean ± standard deviation, and statistical significance was determined using Student's t-test method.
결과 및 고찰Results and Discussion
일반증상 관찰General symptoms observation
실험 전기간 동안 모든 군에서 폐사한 동물은 없었다. 귀뚜라미 추출물 투여기간 동안 모든 군에서 아무런 임상증상을 관찰할 수 없었으며, TCDD를 투여하고 관찰기간 동안은 TCDD 투여한 모든 군에서 피모의 거칠어짐과 체중의 손실이 관찰되었으며, 특히 TCDD 단독투여군에서 이러한 외관상의 변화가 두드러지게 나타났다.None of the animals died in all groups during the experimental period. No clinical symptoms were observed in all groups during the cricket extract, and during the observation period TCDD and TCDD were observed for the roughness and loss of body weight, especially in the TCDD alone group. Changes in appearance were noticeable.
체중변화Weight change
귀뚜라미 추출물 투여기간 동안 모든 군의 체중은 지속적으로 증가하였으나, TCDD를 투여하고 14일의 관찰기간 동안에는 음성대조군(G1)을 제외한 모든 군에서 TCDD 투여 후 7일째부터 체중의 지속적인 감소가 관찰되었다. TCDD 투여 후 14일째에는 음성대조군의 체중(361.74±23.92g)에 비해 TCDD 단독투여군(G2 ; 317.78±21.53g)에서 유의적인 체중의 감소가 관찰되었으며(P<0.01), 귀뚜라미 추출물 50㎎(G3 ; 저용량군) 또는 100㎎(G4 ; 중용량군)에서도 유의적인 감소(저용량군 ; 321.42±35.59g 및 중용량군 ; 325.30±25.20g)가 관찰되었다(P<0.05). 그러나 귀뚜라미 추출물 200㎎(G5 ; 고용량군)에서는 이러한 체중의 감소가 다소 억제되고 있는 경향을 나타내었다. 이를 도 1 및 표 2에 나타내었다.During the cricket extract administration, the body weight of all groups increased continuously, but during the 14-day observation period with TCDD, all groups except negative control group (G1) showed a continuous decrease in body weight after 7 days of TCDD administration. On the 14th day after TCDD administration, significant weight loss was observed in the TCDD alone group (G2; 317.78 ± 21.53g) compared to the body weight of the negative control group (361.74 ± 23.92g) (P <0.01), and cricket extract 50mg (G3). (Low dose group; 321.42 ± 35.59g and medium dose group: 325.30 ± 25.20g) in 100 mg (G4; medium dose group) (P <0.05). However, the cricket extract 200 mg (G5; high-dose group) showed a tendency to suppress this weight loss somewhat. This is shown in Figure 1 and Table 2.
혈액생화학적 검사Blood biochemical test
혈액생화학적 검사에 있어 G2군(744.46± 314.83IU/L)의 AST 활성도는 G1에 비해 유의성 있게 증가하였으나(P<0.01), G3군(257.74± 145.23IU/L), G4군(195.84± 145.23IU/L) 및 G5군(289.60± 110.72IU/L)에서는 G2군에 비해 유의성 있게 감소하였다(P<0.01). 또한 ALT 활성도에 있어서도 귀뚜라미 추출물 투여로 G3군(46.55± 13.73IU/L), G4군(37.93± 6.24IU/L) 및 G5군(39.75± 6.35IU/L)에서 G2군(75.63± 26.59IU/L)에 비해 유의성 있게 감소하는 경향을 보여주었다(G3 및 G5군 ; P < 0.05, G4군 ; P < 0.01). 이를 도 2 및 표 3에 나타내었다.AST activity of G2 group (744.46 ± 314.83IU / L) was significantly increased compared to G1 (P <0.01), but G3 group (257.74 ± 145.23IU / L) and G4 group (195.84 ± 145.23). IU / L) and G5 group (289.60 ± 110.72IU / L) significantly decreased compared to G2 group (P <0.01). In addition, the cricket extract was administered in G3 group (46.55 ± 13.73IU / L), G4 group (37.93 ± 6.24IU / L) and G5 group (39.75 ± 6.35IU / L) in ALT activity. L) showed a tendency to decrease significantly (G3 and G5 group; P <0.05, G4 group; P <0.01). This is shown in Figure 2 and Table 3.
상대 장기중량의 변화 Change in relative organ weight
간장의 상대 장기중량의 변화에 있어 G2군(4.56± 0.37%) 및 G3군(5.01± 0.36%), G4군4.74± 0.17%) 및 G5군(4.36± 0.76%) 모두에서 음성대조군(2.75± 0.14%)에 비해 유의적으로 증가하는 경향을 나타내었다(P < 0.01). 그러나 이러한 장기중량의 증가는 G5군에서 다소 감소하고 있는 경향을 보여주었다. 이를 도 3 및 표 4에 나타내었다.Changes in the relative organ weight of the liver were negative in the G2 group (4.56 ± 0.37%), G3 group (5.01 ± 0.36%), G4 group 4.44 ± 0.17%) and G5 group (4.36 ± 0.76%). 0.14%) showed a tendency to increase significantly (P <0.01). However, this increase in organ weight tended to decrease somewhat in the G5 group. This is shown in Figure 3 and Table 4.
병리조직 검사Histopathology
간장의 병리조직학적 검사에 있어 G2군은 간세동이(portal triad) 주변을 위주로 해서 염증세포의 침윤(inflammatory cell infiltrations)이 관찰되었으며, 이러한 염증세포는 간세동이 주변뿐만 아니라 간소엽 전반에 걸쳐 소상(focal)으로 침윤되는 양상을 나타내었다. 또한 간소엽 전반에 걸쳐 심한 공포화(severe vacuolations) 현상이 관찰되었다. 그러나 이러한 병변은 귀뚜라미 추출물의 투여로 인해 억제되는 경향을 나타내었으며, 특히 귀뚜라미 추출물을 고농도로 투여한 G5군에서 염증세포의 침윤 및 공포화 현상이 현저히 감소하는 경향을 나타내었다.In histopathological examination of the liver, G2 group was observed around the portal triad, and inflammatory cell infiltrations were observed. Infiltrate into focal phases. Severe vacuolations were also observed throughout the lobules. However, these lesions showed a tendency to be inhibited by the administration of cricket extracts, and especially in the G5 group administered with high concentration of cricket extracts, the infiltration and phobia of inflammatory cells tended to be markedly reduced.
TCDD는 현재까지 사용되고 있는 모든 동물종에서 간장의 비대를 일으키는데 이는 TCDD가 씨토크롬 피-450(cytochrome P-450) 효소계에 영향을 미침으로써 유발되는 무과립형질내세망(SER)의 비대로 인한 간실질세포의 과형성과 비대에 기인하는 것으로 알려져 있다. 또한 TCDD로 인해 간장이 손상을 받으면 간세포의 파괴 내지 염증에 기인한 세포막의 투과성이 항진되어 ALT, AST 등의 효소를 포함한 세포내 물질이 혈중으로 유출되어 효소들의 혈중농도와 활성이 증가하게 된다. 본 발명의 실험에서도 역시 TCDD의 투여로 인해 이러한 간장의 비대와 그로 인한 상대 장기중량의 증가, 그리고 혈중 효소 활성도의 증가가 나타났으며 이러한 경향은 본 발명에 따른 귀뚜라미 추출물의 투여로 인해 개선되는 경향을 나타내었다. 또한 병리조직학적 검사에 있어서도 G2군에 비해 G3군 내지 G5군에서 귀뚜라미 추출물의 투여로 인해 간세포의 손상이 억제되는 경향을 보였으며 특히 G5군에서 현저히 억제되는 경향을 나타내었다. 도 4는 본 발명의 실시예들에서 G1군(TCDD 처리없이 귀뚜라미 추출액이 포함되지 않은 생리식염수만을 쥐에게 경구투여한 군)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 100배율로 확대하여 촬영한 사진으로 도 4(A)는 간세동이를 도 4(B)는 중심동맥 부분을 보여주고 있다. 어떠한 손상도 관찰되지 않음을 확인할 수 있었다.TCDD causes hepatic hypertrophy in all animal species used to date, due to hypertrophy of SER caused by TCDD affecting the cytochrome P-450 enzyme system It is known to be due to hyperplasia and hypertrophy of parenchymal cells. In addition, when TCDD damages the liver, the permeability of the cell membrane due to the destruction or inflammation of the liver cells is enhanced, and intracellular substances including enzymes such as ALT and AST are leaked into the blood to increase blood concentration and activity of the enzymes. In the experiments of the present invention, the administration of TCDD also resulted in such an increase in hepatic hypertrophy and thus an increase in relative organ weight, and an increase in blood enzyme activity. This tendency is improved by administration of the cricket extract according to the present invention. Indicated. In addition, the histologic examination showed a tendency of inhibiting hepatocyte damage due to the administration of cricket extract in the G3 group to the G5 group compared to the G2 group, especially in the G5 group. Figure 4 in the embodiments of the present invention stained liver tissue of rats of the G1 group (group orally administered to rats only saline containing no cricket extract without TCDD treatment) with hematoxylin / eosin staining reagent and 100 times 4 (A) shows the liver defibrillation and FIG. 4 (B) shows the central artery part. It was confirmed that no damage was observed.
도 5는 본 발명의 실시예들에서 G2군(귀뚜라미 추출액이 포함되지 않은 생리식염수만을 쥐에게 경구투여하였으며, 그후에 TCDD를 주사한 그룹)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 확대하여 촬영한 사진으로 도 5(A)는 100배율의 확대사진이고, 도 5(B)는 200배율의 확대사진이다. 도 5에서는 심각한 정도의 공포화 현상(검은색 화살표)과 염증세포 침윤현상(청색 화살표)이 관찰됨을 확인할 수 있었다. Figure 5 in the embodiments of the present invention the liver tissue of the G2 group (oral administration of physiological saline not containing the cricket extract, and then injected with TCDD) stained with hematoxylin / eosin staining reagent 5 (A) is an enlarged photograph of 100 times, and FIG. 5 (B) is an enlarged photograph of 200 times. In FIG. 5, it was confirmed that severe phobias (black arrows) and inflammatory cell infiltration (blue arrows) were observed.
도 6은 본 발명의 실시예들에서 G4군(귀뚜라미 추출액 100㎎/㎏을 쥐에게 경구투여하였으며, 그후에 TCDD를 주사한 그룹)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 100배율로 확대하여 촬영한 사진으로, 도 6(A)는 간세동이를 도 6(B)는 중심동맥 부분을 보여주고 있다. 약한 정도의 공포화 현상과 염증세포 침윤현상이 관찰됨을 확인할 수 있었다.Figure 6 in the embodiments of the present invention the liver tissue of the G4 group (Cricket extract 100mg / kg orally administered to the rat, then injected with TCDD) mice stained with hematoxylin / eosin staining reagent and 100 6 (A) shows the liver defibrillation and FIG. 6 (B) shows the central artery part. A slight degree of phobia and inflammatory cell infiltration were observed.
도 7은 본 발명의 실시예들에서 G5군(귀뚜라미 추출액 200㎎/㎏을 쥐에게 경구투여하였으며, 그후에 TCDD를 주사한 그룹)의 쥐의 간조직을 헤마톡실린/에오신 염색시약으로 염색하고 100배율로 확대하여 촬영한 사진으로, 도 7(A)는 간세동이를 도 7(B)는 중심동맥 부분을 보여주고 있다. 심각한 공포화 현상과 염증세포 침윤현상이 귀뚜라미 추출액에 의하여 정상화되었음을 확인할 수 있었다.Figure 7 in the embodiments of the present invention the liver tissue of rats of the G5 group (Cricket extract 200mg / kg orally administered to the rat, then injected with TCDD) mice stained with hematoxylin /
따라서 본 발명에 따르면 귀뚜라미 추출물은 체중 감소의 억제, 혈중 효소치의 개선, 간의 비대 억제와 그로 인한 간세포 보호 등 다양한 작용을 통하여 대표적 환경독성물질인 TCDD의 간독성에 효과적으로 예방작용을 할 수 있음을 확인할 수 있었으며, 특히 그 유효농도는 200㎎/㎏ 이상으로 나타남을 확인할 수 있었다.Therefore, according to the present invention, the cricket extract can effectively prevent the hepatotoxicity of TCDD, a representative environmental toxic substance, through various actions such as inhibition of weight loss, improvement of enzyme levels in blood, inhibition of hepatic hypertrophy and consequent hepatocyte protection. In particular, the effective concentration was confirmed to be represented by more than 200mg / ㎏.
따라서, 본 발명에 의하면 다이옥신 등과 같은 독성화합물에 의해 유발되는 간독성에 대한 예방효과를 갖는 귀뚜라미 추출물을 포함하는 식품을 제공하는 효과가 있다.Therefore, according to the present invention, there is an effect of providing a food comprising a cricket extract having a prophylactic effect against hepatotoxicity caused by a toxic compound such as dioxins.
이상에서 본 발명은 기재된 구체예에 대해서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속함은 당연한 것이다.
Although the present invention has been described in detail only with respect to the described embodiments, it will be apparent to those skilled in the art that various modifications and variations are possible within the technical scope of the present invention, and such modifications and modifications are within the scope of the appended claims.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040050837A KR100599460B1 (en) | 2004-06-30 | 2004-06-30 | Food composition comprising of extracts of cricket having protective effects against hepatotoxicity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040050837A KR100599460B1 (en) | 2004-06-30 | 2004-06-30 | Food composition comprising of extracts of cricket having protective effects against hepatotoxicity |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060001682A KR20060001682A (en) | 2006-01-06 |
KR100599460B1 true KR100599460B1 (en) | 2006-07-12 |
Family
ID=37104787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040050837A KR100599460B1 (en) | 2004-06-30 | 2004-06-30 | Food composition comprising of extracts of cricket having protective effects against hepatotoxicity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100599460B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160058227A (en) | 2014-11-06 | 2016-05-25 | 한국식품연구원 | Method for preparing cricket product for food and cricket product for food prepared therefrom |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101716763B1 (en) * | 2015-05-13 | 2017-03-15 | 이삼구 | Breeding Method for Crickets Comprising Ginsenoside Type Saponin and Polysaccharide from Panax ginseng and their Extracts and Food Composition |
KR101702851B1 (en) * | 2015-12-09 | 2017-02-06 | 이삼구 | The hair follicle and hair growth promoter composition improved with edible crickets |
KR102070802B1 (en) * | 2017-07-28 | 2020-01-29 | 한국 한의학 연구원 | Composition for improving skin wrinkle or skin moisturizing comprising Gryllus bimaculatus extract as effective component |
-
2004
- 2004-06-30 KR KR1020040050837A patent/KR100599460B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160058227A (en) | 2014-11-06 | 2016-05-25 | 한국식품연구원 | Method for preparing cricket product for food and cricket product for food prepared therefrom |
Also Published As
Publication number | Publication date |
---|---|
KR20060001682A (en) | 2006-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ezeja et al. | Acute and sub-chronic toxicity profile of methanol leaf extract of Gouania longipetala in rats | |
Kalender et al. | Methyl parathion induced nephrotoxicity in male rats and protective role of vitamins C and E | |
Ogutcu et al. | Dichlorvos-induced hepatotoxicity in rats and the protective effects of vitamins C and E | |
Cengiz et al. | Sublethal effects of commercial deltamethrin on the structure of the gill, liver and gut tissues of mosquitofish, Gambusia affinis: a microscopic study | |
Smida et al. | Immunoprotective activity and antioxidant properties of cactus (Opuntia ficus indica) extract against chlorpyrifos toxicity in rats | |
Ekweogu et al. | Ameliorative effect of aqueous leaf extract of Solanum aethiopicum on phenylhydrazine-induced anaemia and toxicity in rats | |
El‐Bialy et al. | Ginseng aqueous extract ameliorates lambda‐cyhalothrin‐acetamiprid insecticide mixture for hepatorenal toxicity in rats: role of oxidative stress‐mediated proinflammatory and proapoptotic protein expressions | |
Kutlu et al. | Comparative evaluation of hepatotoxic and nephrotoxic effects of aroclors 1221 and 1254 in female rats | |
Aukkanimart et al. | Anthelmintic, anti-inflammatory and antioxidant effects of Garcinia mangostana extract in hamster opisthorchiasis | |
Tchamgoue et al. | Costus afer protects cardio-, hepato-, and reno-antioxidant status in streptozotocin-intoxicated wistar rats | |
Abdelrasoul | Modulation of abamectin and indoxacarb-induced toxicity on male albino rats by Moringa oleifera | |
KR100599460B1 (en) | Food composition comprising of extracts of cricket having protective effects against hepatotoxicity | |
Mandal et al. | Targeting of liposomal flavonoid to liver in combating hepatocellular oxidative damage | |
Akinloye et al. | Dose-dependent effects of paraquat on c-reactive protein, some lipid profile parameters and histology of tissues in male albino rats. | |
Nur et al. | The effect of caffeic acid phenethyl ester (CAPE) on hepatic histopathology and oxidative stress in rats treated with malathion | |
Kolade et al. | Protective Effects Of Curcumin Against Benzopyrene Induced Liver Toxicity In Albino Rats. | |
Ahmad | Polygonum amplexicaule extract: an effective herbal cure to CCl4 induced liver damage in vivo | |
Serges et al. | Hepatoprotective and antioxidant effects of Commelina diffusa Burm extracts on gentamicin-induced liver damage in rats | |
Riaz et al. | 18. Histopathological alteration in organs of adult male frog after exposure to alpha-cypermethrin | |
Bajpai et al. | Protective effect of heat-treated cucumber (Cucumis sativus L.) juice against lead-induced detoxification in rat model | |
Kanife et al. | Effects of Ethanol Extracts of Healthy and Infected Panicum maximum (Jacq.) Floret on liver and kidney function profile and histopathology in Sprague-dawley rats | |
Saenphet et al. | Acute toxicity and histopathological changes in livers of frog tadpoles (Hoplobatrachus rugulosus) exposed to bioinsecticides derived from Azadirachta indica A. Juss., Stemona curtisii Hook. F., and Mammea siamensis | |
Shipelin et al. | Protective Potential and Antidiabetic Activity of Bilberry Leaves in Zucker Rats | |
Okolonkwo | The preventive effect of vitamin C on the cellular and functional integrity of kidney cells in rats following repeated exposure to paraquat | |
Bashandy et al. | BETA CAROTENE AND HESPERIDIN ANTIOXIDANTS MITIGATE HEPATOTOXIC EFFECTS OF IMIDACLOPRID IN MALE RATS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120518 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130516 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140723 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150626 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160704 Year of fee payment: 11 |